Literature DB >> 28748715

Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study.

Shuling Li1, Julia T Molony1, Karynsa Cetin2, Jeffrey S Wasser3, Ivy Altomare4.   

Abstract

OBJECTIVE: Immune thrombocytopenia (ITP) is characterized by low platelet counts and a tendency toward increased bleeding and bruising. We aimed to describe bleeding frequency and use of rescue ITP therapy to treat or prevent bleeding in elderly ITP patients in a real-world setting.
METHODS: Using Medicare 20% sample data, 2007-2012, we identified elderly (ages ≥67 years) Medicare fee-for-service enrollees diagnosed with primary ITP between 1 January 2009 and 30 September 2012. Bleeding-related episodes (BREs) were defined as ≥1 bleeding event or use of ITP therapies commonly considered for rescue or emergency therapy. BRE rates were examined for the cohort overall, by time since ITP onset, and by splenectomy status. Patients were followed from ITP onset until the earliest of death, disenrollment from fee-for-service coverage, or 31 December 2012.
RESULTS: We identified 3007 elderly patients diagnosed with primary ITP (mean [SD] age: 79.6 [7.5] years; 55% female); 2178 (72%) experienced at least one BRE (8867 BREs); 92 (3%) underwent splenectomy. Nearly half of BREs were defined by rescue therapy use alone. The overall rate was 1.72 BREs per patient-year (95% CI; 1.68-1.75); rates were higher during the first 3 months after ITP onset and after splenectomy.
CONCLUSION: Elderly ITP patients experienced about two BREs per patient-year after ITP onset. Most patients experienced at least one BRE. These real-world results demonstrate the importance of examining both bleeding and use of rescue or emergency ITP therapy in the assessment of disease burden in elderly patients with ITP.

Entities:  

Keywords:  Bleeding-related episodes; Medicare; immune thrombocytopenia

Mesh:

Year:  2017        PMID: 28748715     DOI: 10.1080/03007995.2017.1360852

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  4 in total

1.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

2.  Treatment Patterns Among Adults with Primary Immune Thrombocytopenia Diagnosed in Hematology Clinics in the United States.

Authors:  Leah J McGrath; Karynsa Kilpatrick; Robert A Overman; Diane Reams; Anjali Sharma; Ivy Altomare; Jeffrey Wasser; M Alan Brookhart
Journal:  Clin Epidemiol       Date:  2020-05-05       Impact factor: 4.790

Review 3.  Management of immune thrombocytopenia: 2022 update of Korean experts recommendations.

Authors:  Young Hoon Park; Dae-Young Kim; Seongkoo Kim; Young Bae Choi; Dong-Yeop Shin; Jin Seok Kim; Won Sik Lee; Yeung-Chul Mun; Jun Ho Jang; Jong Wook Lee; Hoon Kook; On Behalf Of Korean Aplastic Anemia Working Party
Journal:  Blood Res       Date:  2022-03-31

4.  Recombinant Thrombopoietin Effectively Shortens the Time to Response and Increases Platelet Counts in Elderly Patients with Severe Immune Thrombocytopenia.

Authors:  Yang Li; Lihua Sun; Feng Li; Ying Li; Yunhua Hou; Yahong Meng; Xiaohong Fan; Yunfeng Cheng; Fanli Hua
Journal:  J Clin Med       Date:  2022-09-29       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.